Daxor Corporation (DXR)
NASDAQ: DXR · Real-Time Price · USD
9.15
-0.48 (-4.98%)
At close: Jun 27, 2025, 4:00 PM
9.20
+0.05 (0.55%)
After-hours: Jun 27, 2025, 4:06 PM EDT
Company Description
Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing.
The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions.
The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973.
Daxor Corporation was incorporated in 1971 and is headquartered in Oak Ridge, Tennessee. Daxor Corporation is a subsidiary of Estate Of Joseph Feldschuh.
Daxor Corporation
| Country | United States |
| Founded | 1970 |
| Industry | Medical Instruments & Supplies |
| Sector | Healthcare |
| Employees | 37 |
| CEO | Michael Feldschuh |
Contact Details
Address: 109 Meco Lane Oak Ridge, Tennessee 37830 United States | |
| Website | daxor.com |
Stock Details
| Ticker Symbol | DXR |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000027367 |
| CUSIP Number | 239467103 |
| ISIN Number | US2394671034 |
| Employer ID | 13-2682108 |
Key Executives
| Name | Position |
|---|---|
| Michael Richard Feldschuh | Chairman, President and Chief Executive Officer |
| Robert J. Michel CPA, CPA, M.B.A. | Chief Financial Officer, Chief Compliance Officer and Corporate Secretary |
| Jonathan Adam Feldschuh | Chief Scientific Officer and Director |
| Dr. John Lynn Jefferies FACC, M.B.A., M.D., M.P.H. | Chief Medical Officer |
| Linda Cooper | Vice President of Development and Operations |
| Kathryn A. Kornafel | Senior Vice President of Marketing and Commercial Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 13, 2025 | 40-17F2 | Filing |
| Jun 12, 2025 | 40-17F2 | Filing |
| Jun 11, 2025 | 40-17F2 | Filing |
| Jun 6, 2025 | DEF 14A | Other definitive proxy statements |
| May 27, 2025 | NPORT-P | Monthly Portfolio Investments Report on Form N-PORT (Public) |
| Mar 14, 2025 | N-CEN | Filing |
| Mar 3, 2025 | N-CSR | Filing |
| Mar 3, 2025 | NPORT-P | Monthly Portfolio Investments Report on Form N-PORT (Public) |
| Jan 22, 2025 | NPORT-P | Monthly Portfolio Investments Report on Form N-PORT (Public) |
| Nov 21, 2024 | NPORT-P | Monthly Portfolio Investments Report on Form N-PORT (Public) |